NM-002
NM-002 is a metabolite of prodrug NM-001 , with NIR emission. NM-002 generates through activates the prodrug NM-001 by overexpressed Cathepsin B (CTSB) within tumor cells. NM-002 has no toxicity towards tumor cells and can escape from the lysosomes into the cytoplasm. NM-002 can be used for real-time drug release monitoring research[1].
Product Specifications
UNSPSC
12352005
Target
Drug Metabolite
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer
Smiles
OC1=CC=C(C[C@@H](NC([C@@H](NC2=O)CC(O)=O)=O)C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(NC2)=O)=O)CCCCNC(CCC3=CN(CCOCCOCCOCCOC4=CC(OC(/C=C/C5=CC(Cl)=C(O)C(CO)=C5)=C/C6=C(C#N)/C#N)=C6C=C4C(C)(C)C)N=N3)=O)=O)C=C1
Molecular Formula
C65H81ClN14O16
Molecular Weight
1349.88
References & Citations
[1]Zhai W, et al. Cathepsin B-Activated Prodrug for Precision Tumor Theranostics. J Med Chem. 2025 Oct 23;68 (20) :21829-21839.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040391-100 1x 100 µL
CD81 / TAPA-1 (1.3.3.22), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040034-100 1x 100 µL
Cytokeratin 8/18 (C-51), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470745-100 1x 100 µL
CD45 / LCA (2B11 + PD7/26), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details